Lakefront Biotherapeutics (GLPGF) Non-Current Deferred Tax Liability (2013 - 2025)

Lakefront Biotherapeutics (GLPGF) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $20.2 million the latest figure, recorded in Q2 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $20.2 million in Q2 2025; TTM through Jun 2025 was $20.2 million, a N/A change from a year earlier, with the FY2024 full-year figure at $22.4 million, down 11.96% from the prior year.
• Non-Current Deferred Tax Liability was $20.2 million for Q2 2025 at Lakefront Biotherapeutics, up from $19.7 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $27.6 million in Q3 2023 and troughed at $19.7 million in Q1 2025.
• A 4-year average of $22.7 million and a median of $22.1 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability advanced 23.56% in 2023 and dropped 20.26% in 2025, its largest moves.
• Over 4 years, Non-Current Deferred Tax Liability stood at $20.6 million in 2022, then increased by 23.56% to $25.4 million in 2023, then decreased by 13.08% to $22.1 million in 2024, then declined by 8.34% to $20.2 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $20.2 million (Q2 2025), $19.7 million (Q1 2025), and $22.1 million (Q4 2024), per Business Quant data.